CONTENTS
53.
Direct to patient: the rocky road to remote drug delivery in clinical trials Sending investigational drugs directly to study participants is yet to reach its full potential, even in trials that would benefit, argues Reynald Castañeda.
57.
Remote clinical trial monitoring uptake rises but validation questions swirl DCT Adoption Tracker: Clinical Trials Arena reviews the burgeoning trend of remote monitoring.
61. 62.
Chapter 3: Medical devices
The CRO of tomorrow CROs must rise to the challenge of adapting to a changing landscape, according to Excelya.
65.
New UK medical device regulation spells potential trial concerns for some IVD players Forthcoming UK medical device regulations draw some praise from the industry along with caution.
67.
How to extract data insights that could score your next licensing deal or investment Why an integrated and interoperable data collection system could make all the difference.
70.
Patient advisers: could they change the face of medtech trials? Exploring new guidance on integrating patient advisers in medical device clinical studies, and what value this could add.
82.
72.
Empower your next study with a truly unified system Get the lowdown on Axiom Metrics’ e-clinical solutions.
75. 77.
Chapter 4: Decentralised clinical trials and the future
Who and what is at the crest of the clinical trial decentralisation wave? Clinical Trials Arena has used drug trial public information to find out which decentralised approaches are making waves.
SMART digital adherence technology: improving the speed and accuracy of clinical trials WestRock healthcare explains how SMART packaging solutions could help improve health outcomes.
86.
Trial diversity: it’s time to quit talking and start doing As the US takes steps to improve diversity in clinical trials, inequities due to economic factors and race will need to be bridged at institutional levels.
90.
Women’s health clinical trials: breaking down barriers through decentralisation Socioeconomic factors mean women tend to be harder to recruit for clinical trials, but decentralised studies can help ease barriers to participation.
93. Suppliers’ directory
Outsourcing in Clinical Trials Handbook | 5
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76 |
Page 77 |
Page 78 |
Page 79 |
Page 80 |
Page 81 |
Page 82 |
Page 83 |
Page 84 |
Page 85 |
Page 86 |
Page 87 |
Page 88 |
Page 89 |
Page 90 |
Page 91 |
Page 92 |
Page 93 |
Page 94 |
Page 95 |
Page 96 |
Page 97 |
Page 98 |
Page 99 |
Page 100
